LTBP1

aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution

Retrieved on: 
星期二, 三月 21, 2023
Pressure, Drug development, Small RNA, Transforming growth factor beta, Fibroblast, Cell, DARS, ATyr Pharma, Extracellular matrix, Fibrosis, Biology, Poster, Pharmaceutical industry, LTBP1, Research

SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Leslie A. Nangle, Ph.D., Vice President, Research, will present findings from its platform in an oral presentation and poster at the Keystone Symposia on Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, which is scheduled to take place March 19 – 23 in Banff, Alberta, Canada.

Key Points: 
  • ATYR0101 was found to bind to human fibroblasts and extracellular matrix deposited by fibroblasts via novel binding of latent transforming growth factor beta binding protein 1 (LTBP1).
  • LTBP1 is an extracellular matrix protein and key regulator of transforming growth factor beta (TGF-β), a central player in the pathogenesis of fibrotic diseases.
  • aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Retrieved on: 
星期四, 三月 9, 2023
Transforming growth factor beta, EST, Medicine, IND, ATyr Pharma, Kyorin, European Medicines Agency, Conference, Clinical trial, Sarcoidosis, ILD, DC, Diagnosis, Interest, Food and Drug Administration, Systemic scleroderma, SAN, Committee, D, EMA, Fibrosis, Patient, FDA, Research, PST, Investigational New Drug, European Patent Office, Disease, American Thoracic Society, Food, Small RNA, European Patent Convention, Patent, Civil service commission, ATS, European Commission, Exercise, Investment, DARS, Scleroderma, Tokyo International Conference on African Development, Safety, Pharmaceutical industry, LTBP1, EU

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.
  • This achievement triggered a $10.0 million milestone payment to aTyr in the fourth quarter.
  • Based on the Company’s current operational plans and existing cash, aTyr believes the Company’s cash runway will extend into 2026.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment

Retrieved on: 
星期四, 十二月 15, 2022
Scripps Research, Drug discovery, SAN, ATyr Pharma, Disease, Molecular medicine, DARS, Transforming growth factor beta, RNA transfection, Fibrosis, Research, Risk, Biology, COVID-19, Pharmaceutical industry, LTBP1

SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform. The target for a naturally occurring fragment of Aspartyl-tRNA Synthetase (DARS) was identified as latent transforming growth factor beta binding protein 1 (LTBP1).

Key Points: 
  • SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform.
  • The target for a naturally occurring fragment of Aspartyl-tRNA Synthetase (DARS) was identified as latent transforming growth factor beta binding protein 1 (LTBP1).
  • The company expects to present additional findings around the interaction between LTBP1 and this fragment of DARS at an upcoming scientific conference.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.